Fig. 2From: The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIscfDNA levels and its association with best response of patients in the overall population (A) and in immunotherapy (B) and VEGFR-TKIs (C) treated cohortsBack to article page